Inventurus Knowledge Solutions Limited has informed the Exchange about Transcript of the Q4 FY25 Earnings Conference Call.
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IKS Health filed the transcript of its Q4 FY25 earnings call held on May 16, 2025. Q4 revenue came in at INR 724 crores, up 17% year-on-year, with EBITDA of INR 226 crores (up 68% YoY) and EBITDA margin around 31%. Full-year FY25 revenue was INR 2,664 crores (47% YoY growth), EBITDA ~INR 791 crores (~50% YoY growth) at a 29.7% margin, and PAT of INR 486 crores (up ~31%). Margins expanded sharply from a 24% pro-forma base in FY24, driven by AQuity integration, shift to tech-led/AI-native operations, and customer base right-sizing (from 850 to ~700 customers). Management highlighted new platform wins including Sky Lakes, Western Washington Medical Group, Platinum Derm, OrthoNY, and GI Alliance, and early cross-sell traction with four AQuity clients. Net debt fell from INR 860 crores to INR 560 crores; ROE stood at 27.2%. Management declined to provide forward guidance, citing market immaturity.
Strong quarter and full-year results reinforce the AQuity integration story, with clear margin expansion and debt reduction validating the capital-efficient platform thesis. Multiple marquee platform wins and cross-sell momentum are early positive signals for FY26 growth, though management's refusal to provide guidance may cap near-term excitement.